Vanucizumab
Based on 1 Customer Validation
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 95.12%
- CAS. Nr.: 1448221-05-3
- Molecular Weight:146.89 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover
Human
ANG2 & VEGFA
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID beige mice bearing Colo205 cells[2]
-
Dosage:20 mg/kg
-
Administration:i.p.; once weekly; for 6 weeks
-
Result:Showed tumor growth inhibition.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover
ELISA, FACS, Functional assay
-
Immobilized Human VEGFA, His Tag can bind Vanucizumab. The EC50 for this effect is 4.575 ng/mL. -
Immobilized Human ANGPT2, His Tag can bind Vanucizumab. The EC50 for this effect is 78.70 ng/mL. -
Flow cytometric analysis of 1X106 HeLa cells with Vanucizumab (HY-P99330, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS. Nr. 1448221-05-3
-
Appearance Liquid
-
Molecular Weight 146.89 kDa
-
Color Colorless to light yellow
-
SMILES
[Vanucizumab]
-
Synonyms
Anti-Human VEGFA Recombinant Antibody; RO5520985
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. [Content Brief]
[2]. Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Powered by Bioz